|
KMID : 0359920080270010110
|
|
Korean Journal of Nephrology
2008 Volume.27 No. 1 p.110 ~ p.116
|
|
|
’Rescue Therapy’ with Mycophenolate Mofetil in Non-transplant Renal Disease Patients Experienced Conventional Immunosuppressive Treatments : Clinical Observation
|
|
Yang Byeong-Yun
Kang Jin
Song Sang-Heon
Lee Dong-Won
Kwak Ihm-Soo
|
|
|
Abstract
|
|
|
Purpose: Mycophenolate mofetil (MMF) is thought to have not only low frequency of adverse side effects but also have equal efficacy to other conventional immunosuppressants (CIS). But It’s hard to conclude that CIS may be replaceable with MMF. So we inquired into another aspect of MMF as ’Rescue therapy’ in non-transplant renal diseases.
Methods: Twenty nine patients with non-transplant renal diseases received MMF therapy between January 2000 and April 2007. Eighteen patients who had received MMF more than 6 months were included. Sixteen of the 18 patients included were resistant to CIS and two were patients who maintained complete remission (CR) with MMF because of the adverse side effects of CIS. Treatment outcome was evaluated by dip-stick urine test. CR was defined by negative or trace, partial remission (PR) by 1 positive and treatment failure (TF) by more than 1 positive.
Results: Eleven of the resistant 16 patients had shown CR (69%) and maintained CR. Two of maintenance therapy with MMF had kept CR more than 12 months. The proportions of the patients who had shown decreased proteinuria in each treatment duration were 69% for 3 months (p=0.005), 81% for 6 months (p=0.001), 86% for 9 months (p=0.002) and 91% for 12 months (p=0.004), respectively. There were few adverse effects.
Conclusions: We observed the efficacy of MMF in decreasing proteinuria and maintaining CR as ’Rescue therapy’ for previously treated non-transplant renal disease patients with CIS. Large controlled clinical trials are expected for defining this effect.
|
|
|
KEYWORD
|
|
|
Mycophenolate mofetil, Kidney diseases, Proteinuria
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|